Analytical Data
-
Gene name
KYNU/Kynureninase
- Application
-
Alternative Names
L-Kynurenine Hydrolase
-
Species
Human
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q16719
-
Expression Region
Met1~Asn465
-
Molecular Weight
56kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Kynureninase (KYNU) is an enzyme involved in the kynurenine pathway, a critical metabolic pathway responsible for the degradation of tryptophan into several neuroactive metabolites. The study of KYNU is gaining attention due to its significant role in various physiological and pathological processes, including neurodegenerative diseases, mood disorders, and immune responses. Kynurenine, its primary substrate, can influence neurotransmitter systems and has been implicated in the pathogenesis of disorders like schizophrenia and depression. However, the precise functions and regulatory mechanisms of KYNU remain poorly understood, primarily due to the lack of sufficient recombinant protein for in-depth studies. By producing recombinant KYNU, researchers aim to explore its enzymatic properties, substrate specificity, and potential as a therapeutic target. This research could lead to novel insights into the kynurenine pathway's impact on mental health and neuroinflammation, thereby paving the way for new therapeutic strategies to address these complex conditions. Overall, the generation of KYNU recombinant protein is a crucial step towards unraveling the intricacies of kynurenine metabolism and its implications for human health.
